
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vedolizumab
Therapeutic Area : Immunology
Study Phase : Phase III
Recipient : Polpharma Biologics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Polpharma and MS Pharma Sign Licensing Agreements for Proposed Biosimilars
Details : The agreement aims to commercialize its biosimilar candidates, vedolizumab (PB016), ocrelizumab (PB018), and guselkumab (PB019), in the MENA region.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
September 02, 2025
Lead Product(s) : Vedolizumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Recipient : Polpharma Biologics
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Omalizumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Recipient : Kashiv BioSciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Kashiv and MS Pharma Enter into MENA License and Supply Agreement for ADL-018
Details : MS Pharma will be responsible for the licensing, distribution, and commercialization of ADL-018, biosimilar candidate to Xolair (omalizumab), in the MENA region.
Product Name : ADL-018
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
August 05, 2025
Lead Product(s) : Omalizumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Recipient : Kashiv BioSciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Recipient : Klinge Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
MS Pharma Partners for FYB203 Biosimilar Commercialization in MENA Region
Details : MS Pharma becomes a partner for the commercialization of FYB203, Formycon’s Biosimilar to Eylea® (Aflibercept), in the MENA Region for the treatment of neovascular age-related macular degeneration.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
May 14, 2024
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Recipient : Klinge Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Recipient : Polpharma Biologics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the exclusive agreement, MS Pharma will be responsible for the registration and commercialization of FYB201/CHS-201 (Ranibizumab), in the Middle East and North African countries. MS Pharma will start the registration procedures in MENA immediately.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
December 14, 2021
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Recipient : Polpharma Biologics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
